Related Experiment Video
Updated: Jul 25, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
11.7K
INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema
R Lejoyeux1, E Diwo1, H Vallet2
1a Ophthalmology Department, Reference Center for Rare Diseases OPTHARA, Pitié-Salpétrière Hospital , Paris VI University , Paris , France.
Ocular Immunology and Inflammation
|August 11, 2018
Summary
Infliximab and adalimumab showed similar efficacy in treating refractory uveitis-related macular edema. Both treatments led to comparable reductions in central foveal thickness over 24 months.
Area of Science:
- Ophthalmology
- Immunology
- Medical Retina
Background:
- Refractory uveitis can cause macular edema, impacting vision.
- Anti-tumor necrosis factor (TNF) agents are used for uveitis treatment.
- Infliximab and adalimumab are biologic therapies targeting TNF.
Purpose of the Study:
- To compare the efficacy of infliximab versus adalimumab.
- To evaluate treatment outcomes in patients with refractory uveitis-related macular edema.
Main Methods:
- Retrospective study of 25 patients with refractory uveitis-related macular edema.
- Treatment groups: infliximab (13 patients) and adalimumab (12 patients).
- Ophthalmologic examination, OCT, and angiography assessed at baseline, 6, and 24 months.
Main Results:
- No significant difference in treatment response at 6 months (50% adalimumab, 61% infliximab).
- Comparable median central foveal thickness decrease at 6 and 24 months for both drugs.
- No statistically significant differences in efficacy between infliximab and adalimumab.
Conclusions:
- Infliximab and adalimumab demonstrate similar efficacy.
- Both agents are viable options for refractory uveitis-related macular edema.
- Further research may explore long-term outcomes and safety profiles.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...